Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression

Transplantation

Volumn 84, Issue 6, 2007, Pages 706-714

  Hernández, Domingo ^a,b,c   Miquel, Rosa ^a   Porrini, Esteban ^a   Fernández, Ana ^d   González Posada, José Manuel ^a,c   Hortal, Luis ^d   Checa, María Dolores ^e   Rodríguez, Aurelio ^a,c   García, José Javier ^f   Rufino, Margarita ^a,c   Torres, Armando ^a,b,c  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b Instituto Reina Sofia de Investigación   (Spain)

^c UNIVERSIDAD DE LA LAGUNA   (Spain)

^d HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^e HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^f HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

Author keywords

Basiliximab; Cyclosporine; Immunosuppressive therapy; Kidney transplantation; Renal function; Tacrolimus

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR; URINARY TRACT INFECTION;

ADULT; CALCINEURIN; CARDIOVASCULAR DISEASES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEINURIA; SURVIVAL ANALYSIS; TACROLIMUS;

EID: 34748853697     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000282872.17024.b7     Document Type: Article

References (20)

1. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
2. Gaston RS. Current and evolving immunosuppressive regimens in kidney transplantation. Am J Kidney Dis 2006; 47: S3.
3. Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567.
4. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011.
5. Gaspari F, Ferrari S, Stucchi N, et al. Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant 2004; 4: 826.
6. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
7. Hernandez D, Hanson E, Kasiske MK, et al. Cytomegalovirus disease is not a major risk factor for ischemic heart disease after renal transplantation. Transplantation 2001; 72: 1395.
8. Anonymous. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28: S37.
9. Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809.
10. Gallagher MP, Hall B, Craig J, et al. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004; 78: 1653.
11. Marcen R, Pascual J, Teruel JL, et al. Outcome of cadaveric renal transplant patients treated for 10 years with cyclosporine: Is chronic allograft nephropathy the major cause of late graft loss? Transplantation 2001; 72: 57.
12. Baboolal K, Jones GA, Janezic A, et al. Molecular and structural consequences of early renal allograft injury. Kidney Int 2002; 61: 686.
13. Mohamed MA, Robertson H, Booth TA, et al. TGF-beta expression in renal transplant biopsies: A comparative study between cyclosporin A and tacrolimus. Transplantation 2000; 69: 1002.
14. Gotti E, Perico N, Perna A, et al. Renal transplantation: Can we reduce calcineurin inhibitor/stop steroids? Evidence based on protocol biopsy findings. J Am Soc Nephrol 2003; 14: 755.
15. Yamamoto H, Akazawa S, Yamaguchi Y, et al. Effects of cyclosporin A and low dosages of steroid on posttransplantation diabetes in kidney transplant recipients. Diabetes Care 1991; 14: 867.
16. Pascual J, van Hooff JP, Salmela K, et al. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 2006; 82: 55.
17. Artz MA, Boots JM, Ligtenberg G, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4: 937.
18. Rostaing L, Cantarovich D, Mourad G, et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807.
19. Hardinger KL, Schnitzler MA, Miller B, et al. Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 2004; 78: 136.
20. de Mattos AM, Prather J, Olyaei AJ, et al. Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors. Kidney Int 2006; 70: 757.